Articles

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

Learn about the evolving cyber-threat landscape affecting the pharmaceutical industry and the recommended approach to addressing those threats.

Top cybersecurity threats, challenges pharma companies need to address

There are three phases of digital transformation needed to reimagine business models, achieve better performance, and create long-term sustainable advantage. It starts with changing our labs—the technologies, processes, ways of working, and data solutions.


Defining the 'Lab of the Future'

Tips for tailoring eConsent for  Optimal Patient Centricity

According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. 
 
In conclusion - a decentralized consent process is here to stay. 
 
Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.

Why eConsent Primes Studies & Patients for Success

In this paper, learn about a variety of genetic analysis methods and how they’re valuable in ensuring that ex vivo human cells used for cell‑based therapies are correctly identified, have the correct characteristics, and are free of contaminants.

Download the white paper and read more about the importance of quality control (QC) for isolated human cells and tissues.

Quality control for human cell lines and other human samples manipulated ex vivo

For biopharmaceutical developers, optimizing R&D investment in new technologies is an essential way to gain and sustain a competitive edge. Clinical trials present a tremendous opportunity to leverage advanced genetics technologies and practices to improve efficiency and reduce costs. 

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

Past the Podium: A New Tech Stack for Medical Affairs in the Future

Biometrics & AI Technologies in Cancer Treatment

 is igniting a new era in human health with industry-leading Organ-on-a-Chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease — offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Pioneered at the Wyss Institute for Biologically Inspired Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, Organ-on-a-Chip technology is assisting researchers across academia, pharma, and government industries through its predictive power and ability to recreate true-to-life human biology.

All Whitepapers